PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ploscurrentsLink to Publisher's site
 
PLoS Curr. 2009 December 17; 1: RRN1137.
PMCID: PMC2795773
Influenza

Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.

Abstract

This work contributes informed estimates to the current debate about the pandemic (H1N1) 2009 mass immunization program’s economic merits. We performed a cost-utility analysis of the (H1N1) 2009 mass immunization program in Ontario, Canada’s most populous province. The analysis is based on a simulation model of a pandemic (H1N1) 2009 outbreak, surveillance data, and administrative data. We consider no immunization versus mass immunization reaching 30% of the population. Immunization program costs are expected to be $118 million in Ontario. Our analysis indicates this program will reduce influenza cases by 50%, preventing 35 deaths, and cutting treatment costs in half. A pandemic (H1N1) 2009 immunization program is likely to be highly cost-effective.

Background

Since the H1N1 vaccine approval on October 21, 2009 in Canada, the largest vaccination program in the country’s history has been rolled out. The vaccine’s efficacy and the program’s effectiveness [1] have been estimated. However, in the face of rising vaccination program costs, there is increasing public discussion about whether the program represents good value for the healthcare dollar.

Methods 

We performed a cost-utility analysis from the health care payer perspective perspective in the Canadian province of Ontario (population 13,000,000). This economic evaluation utilized a simulation model of a pandemic (H1N1) 2009 outbreak in a Canada city [2]. Attack rates for symptomatic cases were projected for four age groups under two strategies: (a) no vaccination, and (b) mass vaccination of 10% of the population per week, starting 40 days into the pandemic and lasting until 30% vaccine coverage is reached. We assume it takes 20 days for an individual to develop immunity. Patients with influenza A (H1N1) were treated with oseltamivir. Population-weighted mean predicted attack rates were 21% and 11% for strategies (a) and (b) respectively. Probabilities for health care resource use (office visits, emergency department (ED) visits, hospitalizations, intensive care unit (ICU) admissions, use of extracorporeal membrane oxygenation (ECMO)) and deaths were based on pandemic (H1N1) surveillance data in Ontario and Australia, and Ontario administrative data, covering the entire population of Canada’s most populous province. Hospitalization rates for Ontario were estimated from laboratory-confirmed cases, likely representing a significant underestimate of the true burden of disease. We therefore inflated reported rates 100-fold to account for expected underrepresentation of less severe H1N1 cases among laboratory-confirmed cases. This is consistent with estimates from the United States [3] and produces conservative predictions for number of hospitalizations, ICU admissions and deaths. Program and other costs were drawn from Ontario sources (Ontario Health Insurance Plan (OHIP), Ontario Case Costing Initiative (OCCI) [4]). Utility weights were obtained from the literature [5] and annualized. Years of life lost were calculated using average life expectancy adjusted for quality of life [6].

Main outcome measures were quality adjusted life-years (QALYs), costs in 2009 Canadian dollars, and cost per QALY gained.

Table 1: Predicted pandemic (H1N1) 2009 attack rates in Ontario [2]

Table thumbnail

Table 2: Pandemic (H1N1) 2009 Related Events

Table thumbnail

Note: (a) 1.12 office visits per person (b) 1.17 Emergency Department visits per person (c) overall probability for ICU admission in Australia 0.13, in Ontario for the period August 30 to November 7, 2009: 0.12 (no age-specific rates available); (d) overall probability of death if hospitalized in Australia: 0.038, in Ontario for the period August 30 to November 7, 2009: 0.036 (no age-specific rates available); ED = emergency department; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; OHIP = Ontario Health Insurance Plan; OCCI = Ontario Case Costing Initiative

Table 3: Pandemic (H1N1) 2009 Economic Data

Table thumbnail

ED = emergency department; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; OHIP = Ontario Health Insurance Plan; OCCI = Ontario Case Costing Initiative

Results

Ontario’s H1N1 immunization program is estimated to cost $118 million ($30 per person vaccinated). Immunizing 30% of the population prevents approximately 1.4 million cases, 850 hospitalizations and 35 deaths. This reduces healthcare cost due to illness from $154 million to $77 million and is associated with 24,864 additional quality-adjusted life-years for the population. The incremental cost-effectiveness ratio (ICER) is $1,645 per QALY gained. Results are sensitive to immunization program effectiveness and cost. If the program reduces the number of cases by only 25%, the ICER increases to $6,333 per QALY gained. Finally, if immunization costs are $50 per person vaccinated, the ICER compared to no intervention increases to $4,798 per QALY gained for 30% vaccination coverage. In all sensitivity analyses the ICER remains well below established thresholds, which determine the cost-effectiveness of a program [12].

Table 4: Aggregated Results for Base Case Analysis

Table thumbnail

ED = emergency department; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; QALY = quality-adjusted life year

Table 5: Aggregated Results for Sensitivity Analyses

Table thumbnail

ICER = Incremental cost-effectiveness ratio

Discussion

We estimate that the pandemic (H1N1) 2009 mass immunization program in Ontario, Canada is highly cost-effective under conservative assumptions on healthcare resource use, costs, and mortality. This is consistent with the economic attractiveness demonstrated for seasonal influenza programs [13],[14].

Estimates of hospitalizations and mortality are based on laboratory-confirmed cases. In the base case, we expect 67 deaths. By contrast, the average annual estimated number of deaths related to seasonal influenza in Ontario is 500 to 1,200 ([15], and J.C. Kwong, unpublished). While the number of deaths associated with the 2009 pandemic may be lower in part because of relative sparing of older adults from disease, counting only laboratory-confirmed cases may also cause a significant underestimation. Similarly, we only include costs directly related to the treatment of pandemic (H1N1) cases. For example, the effects of the increased demand on health care services--such as cancelling elective surgery--are not included. Also, because of limited data this analysis also does not include vaccine-associated adverse events. While inclusion of serious adverse events reduces cost-effectiveness, we would not expect it to diminish the fundamental cost-effectiveness of the program if the incidence of such events remains low [2].

Public health physicians and officials have traditionally focused on containing the spread of infectious disease and mitigating disease burden. But those who organize and deliver public health services are also faced with the resource constraints that affect every other part of the healthcare system. We think it is unlikely that economic considerations will ever be, or should ever be uppermost in the minds of those battling a pandemic. However, it is reassuring to know that Canada's response to the current pandemic appears to be reasonable when viewed through the lens of careful stewardship of scarce resources. 

Funding information

This study was supported by an operating grant from the Canadian Institutes for Health Research (CIHR), which provided fellowship support for B. Sander and M. Zivkovic Gojovic. B. Sander also received post-doc funding from MITACS (Mathematics of Information Technology and Complex Systems). D. Fisman holds an Ontario Early Researcher Award funded by the Ontario Ministry of Research and Innovation. R.A. Fowler holds a Clinician Scientist Award from the Ontario Ministry of Health and Long-term Care. J.C. Kwong holds a Career Scientist Award from the Ontario Ministry of Health and Long-term Care and a Research Scholar Award from the Department of Family and Community Medicine, University of Toronto. M. Krahn holds the F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto. Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The researchers are independent from the funders. 

This study was also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.

Competing interests

Beate Sander has held consulting contracts with Hoffmann La-Roche, Switzerland, related to economic evaluations of Tamiflu for treatment and postexposure prophylaxis in epidemics and pandemics. This work involved giving presentations at scientific meetings, for which she received travel assistance and a speaker’s fee. David Fisman holds an Ontario Early Researcher Award funded by the Ontario Ministry of Research and Innovation. Matching funds for this grant were provided by Sanofi-Pasteur, which manufactures influenza vaccines, including vaccine for pH1N1 (for use outside Canada). None declared for Marija Zivkovic Gojovic, Murray Krahn and Chris Bauch.

References

  • Public Health Agency of Canada (2009): Guidance Document on the Use of Pandemic Influenza A (H1N1) 2009 Inactivated Monovalent Vaccine Revised November 13, 2009. Available at: http://www.phac-aspc.gc.ca/alert-alerte/h1n1/vacc/pdf/monovacc-guide-eng.pdf. Accessed 2009 Nov 19.
  • Zivkovic Gojovic M, Sander B, Fisman D, Krahn MD, and Bauch CT. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009 181: 673-680. [PMC free article] [PubMed]
  • Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, et al. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis [serial on the Internet]. 2009 Dec; [Epub ahead of print] [PMC free article] [PubMed]
  • OCCI (Ontario Case Costing Initiative). Costing Analysis Tool. Available from: http://www.occp.com. Last updated September 2009. Accessed October 26, 2009.
  • Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, et al. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2006; 24: 1035-1043. [PubMed]
  • Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. PharmacoEconomics 1999; 15: 369-376. (2008) [PubMed]
  • Tuite A. Estimated Rates of Hospitalization, ICU Admission, and Mortality by Age and Risk Group for 2009 H1N1 in Ontario, April to June 2009.
  • Australian Government, Department of Health and Aging. Australian Influenza Surveillance Summary Report. No.22, 2009, Reporting Period: 3 October 2009 – 9 October 2009. Available from: http://www.healthemergency.gov.au. Accessed November 10, 2009.
  • Kumar A, Zarychanski R, Pinto R, et al. for the Canadian Critical Care Trials Group H1N1 Collaborative. Critically Ill Patients with 2009 Influenza A (H1N1) in Canada. JAMA 2009;302:1872-1879. [PubMed]
  • Statistics Canada. Mortality rate per 1,000 population. Canadian socio-economic information management system (CANSIM). 2008.
  • Waldie P, Alphonso C. Cost of vaccinating nation hits $1.5-billion and climbing. Globe and Mail. Published on Thursday, Nov. 12, 2009 12:00AM EST. Available from: http://www.theglobeandmail.com. Last updated on Friday, Nov. 13, 2009 1:57AM EST. Accessed November 18, 2009.
  • WHO. Cost-effectiveness thresholds. Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 2009 Nov 19.
  • Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 2000; 17: 217-227. [PubMed]
  • Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, et al. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002; 62: 1013-102. [PubMed]
  • Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur RE, et al. The effect of universal influenza immunization on mortality and health care use. PLoS Med 2008; 5: e211. [PMC free article] [PubMed]

Articles from PLoS Currents are provided here courtesy of Public Library of Science